Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Payables (2020 - 2025)

Oncology Institute (TOI) has disclosed Payables for 6 consecutive years, with $35.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 45.02% year-over-year to $35.6 million, compared with a TTM value of $35.6 million through Sep 2025, up 45.02%, and an annual FY2024 reading of $24.3 million, up 68.58% over the prior year.
  • Payables was $35.6 million for Q3 2025 at Oncology Institute, up from $34.9 million in the prior quarter.
  • Across five years, Payables topped out at $35.6 million in Q3 2025 and bottomed at $24707.0 in Q1 2021.
  • Average Payables over 5 years is $15.9 million, with a median of $13.9 million recorded in 2022.
  • Peak annual rise in Payables hit 72216.33% in 2021, while the deepest fall reached 91.43% in 2021.
  • Year by year, Payables stood at $15.6 million in 2021, then plummeted by 39.76% to $9.4 million in 2022, then skyrocketed by 53.96% to $14.4 million in 2023, then surged by 68.58% to $24.3 million in 2024, then soared by 46.5% to $35.6 million in 2025.
  • Business Quant data shows Payables for TOI at $35.6 million in Q3 2025, $34.9 million in Q2 2025, and $29.3 million in Q1 2025.